Core Viewpoint - ProMIS Neurosciences, Inc. is advancing its research on therapies for Alzheimer's disease and other neurodegenerative disorders, presenting findings at the Alzheimer's & Parkinson's Diseases Conference 2026 [1][2]. Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing therapeutic antibodies and vaccines targeting toxic oligomers associated with neurodegenerative diseases [4]. - The company utilizes its proprietary EpiSelect™ platform to identify Disease Specific Epitopes (DSEs) on misfolded proteins, which are implicated in diseases like Alzheimer's, ALS, and Parkinson's [4][8]. Research and Development - The company will present two scientific posters at the AD/PD™ 2026 conference, showcasing its proprietary discovery platform and its approach to targeting toxic misfolded proteins [1][2]. - The lead product candidate, PMN310, is a humanized monoclonal antibody designed to selectively target toxic oligomers while avoiding plaque, potentially reducing amyloid-related imaging abnormalities (ARIA) [5][6]. - PMN310 has received Fast Track designation from the U.S. FDA as of July 2025, indicating its potential in treating Alzheimer's disease [5]. Clinical Trials - ProMIS initiated the PRECISE-AD trial, a Phase 1b clinical study to evaluate the safety and pharmacokinetics of PMN310 in patients with Mild Cognitive Impairment and mild Alzheimer's disease [6][7]. - The trial will assess the effects of PMN310 on biomarkers associated with Alzheimer's pathology and clinical outcomes, with a focus on safety and the risk of ARIA [7]. Presentation Details - The first presentation will focus on a vaccine designed against TDP-43 proteinopathies, while the second will discuss vaccination strategies targeting toxic alpha-synuclein species [3].

Core Insights - ProMIS Neurosciences Inc. has entered into a securities purchase agreement to raise approximately $175 million through the issuance of common shares and warrants, aimed at extending its cash runway into 2028 and supporting key clinical milestones in Alzheimer's disease research [1][4] Financing Details - The financing includes the sale of 6,815,296 common shares at $10.77 each, 100,000 pre-funded warrants at a similar price with a minimal exercise price, and 725,221 common shares sold at $12.13 to affiliates and insiders [2] - The common share warrants have an exercise price of $14.40, are immediately exercisable, and will expire within 60 days of a defined milestone event or on February 3, 2031 [2] - The anticipated upfront gross proceeds from the financing are approximately $75 million, with potential additional proceeds of up to $100 million if all warrants are exercised [4] Investor Participation - The private investment in public equity (PIPE) financing is co-led by Janus Henderson and Ally Bridge Group, with participation from various institutional investors including Deep Track Capital and Wellington Management [3] Clinical Development Plans - ProMIS aims to use the proceeds to complete its Phase 1b clinical study for Alzheimer's disease and to accelerate the development of a subcutaneous formulation of PMN310, with blinded top-line data expected in mid-2026 and 12-month data by the end of 2026 [4]

Core Viewpoint - ProMIS Neurosciences Inc. has announced a one-for-twenty-five reverse stock split to comply with Nasdaq listing requirements and aims to increase the market price of its common shares [1][11]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect at 12:01 a.m. Eastern Time on November 28, 2025, with shares trading on a split-adjusted basis from that date [2]. - The number of outstanding common shares will decrease from approximately 53,811,110 shares to about 2,152,444 shares [3]. - Proportional adjustments will be made to equity incentive plans, stock options, and outstanding warrants in accordance with the reverse stock split [4]. Group 2: Compliance with Nasdaq - ProMIS received a deficiency letter from Nasdaq on January 8, 2025, indicating that its common shares had not maintained the minimum required closing bid price of at least $1.00 [8]. - The company was granted an additional 180-day compliance period until December 29, 2025, to regain compliance with the Bid Price Rule [10]. - The reverse stock split is part of the company's strategy to cure the deficiency and meet Nasdaq's listing standards [11]. Group 3: Shareholder Information - No fractional shares will be issued; shareholders entitled to fractional shares will receive cash instead [5]. - Stockholders with shares held in book-entry form or through a bank or broker will see the effects of the reverse stock split reflected in their accounts without needing to take action [6]. Group 4: Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative disorders, including Alzheimer's disease [13]. - The company utilizes its proprietary target discovery engine, EpiSelect™, to identify novel targets associated with misfolded proteins [13].

Core Insights - ProMIS Neurosciences has appointed Slanix Paul Alex to its Board of Directors, enhancing its strategic vision and investor engagement as it advances its Alzheimer's program, PMN310 [1][2] - The company is approaching key inflection points with planned data readouts in Q2 2026 and Q4 2026 from its PRECISE-AD trial evaluating PMN310 [2] Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing next-generation therapies for Alzheimer's disease and other neurodegenerative disorders [1][4] - The company utilizes its proprietary EpiSelect™ platform to discover therapeutic antibodies and vaccines targeting toxic oligomers associated with neurodegenerative diseases [4][8] Product Development - PMN310 is ProMIS's lead product candidate, a humanized monoclonal antibody designed to selectively target toxic oligomers while avoiding plaque, potentially reducing the risk of amyloid-related imaging abnormalities (ARIA) [6][7] - The PRECISE-AD trial is a Phase 1b clinical study aimed at evaluating the safety, tolerability, and pharmacokinetics of PMN310 in patients with Mild Cognitive Impairment and mild Alzheimer's disease [7] Investment and Leadership - Slanix Paul Alex, with extensive experience in healthcare investment, is expected to provide valuable insights as ProMIS approaches critical clinical milestones [2][3] - Ally Bridge Group, a significant shareholder, has been instrumental in supporting ProMIS's growth and investment strategy [2][3]

Core Points - ProMIS Neurosciences, Inc. has announced a private investment in public equity (PIPE) financing, raising approximately $2.4 million through the issuance of warrants, with total gross proceeds expected to reach $9.2 million when including additional funds from existing warrant exercises [1][3] - The warrants have an exercise price of $1.25 per share, are immediately exercisable, and will expire five years from the date of issuance [2] - Proceeds from the PIPE financing will be utilized to advance the clinical development of PMN310, the company's lead therapeutic candidate, as well as for working capital and general corporate expenses [4] Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing therapeutic antibodies targeting toxic misfolded proteins associated with neurodegenerative diseases, including Alzheimer's disease, ALS, and Parkinson's disease [7] - The company employs a proprietary target discovery engine, EpiSelect™, to identify Disease Specific Epitopes (DSEs) on misfolded proteins, which are implicated in various neurodegenerative conditions [7]

Core Viewpoint - ProMIS Neurosciences Inc. is actively engaged in the development of therapeutic antibodies targeting toxic oligomers linked to neurodegenerative diseases, with a focus on Alzheimer's Disease, ALS, and MSA [1][3]. Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company based in Cambridge, Massachusetts, and Toronto, Ontario, specializing in the discovery and development of therapeutic antibodies for misfolded protein diseases [3]. - The company utilizes its proprietary target discovery engine, EpiSelect™, to identify Disease Specific Epitopes (DSEs) on misfolded proteins associated with various neurodegenerative diseases [3]. Product Development - PMN310 is the lead product candidate for Alzheimer's Disease, designed as a humanized monoclonal antibody that selectively targets toxic oligomers while avoiding plaque, potentially enhancing safety and efficacy compared to other therapies [4]. - The PRECISE-AD trial is a Phase 1b clinical study initiated to evaluate the safety, tolerability, and pharmacokinetics of PMN310 in patients with Mild Cognitive Impairment and mild Alzheimer's Disease [5]. - The trial aims to assess the effects of PMN310 on biomarkers related to Alzheimer's pathology and clinical outcomes, with a primary focus on safety and reduced risk of ARIA due to its non-plaque binding nature [5].